Cargando…

Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception cohort

INTRODUCTION: This study investigated five confirmed rheumatoid arthritis (RA) susceptibility genes/loci (HLA-DRB1, PTPN22, STAT4, OLIG3/TNFAIP3 and TRAF1/C5) for association with susceptibility and severity in an inception cohort. METHODS: The magnitude of association for each genotype was assessed...

Descripción completa

Detalles Bibliográficos
Autores principales: Morgan, Ann W, Robinson, James I, Conaghan, Philip G, Martin, Stephen G, Hensor, Elizabeth MA, Morgan, Michael D, Steiner, Lori, Erlich, Henry A, Gooi, Hock-Chye, Barton, Anne, Worthington, Jane, Emery, Paul
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2888207/
https://www.ncbi.nlm.nih.gov/pubmed/20353580
http://dx.doi.org/10.1186/ar2969
_version_ 1782182637144637440
author Morgan, Ann W
Robinson, James I
Conaghan, Philip G
Martin, Stephen G
Hensor, Elizabeth MA
Morgan, Michael D
Steiner, Lori
Erlich, Henry A
Gooi, Hock-Chye
Barton, Anne
Worthington, Jane
Emery, Paul
author_facet Morgan, Ann W
Robinson, James I
Conaghan, Philip G
Martin, Stephen G
Hensor, Elizabeth MA
Morgan, Michael D
Steiner, Lori
Erlich, Henry A
Gooi, Hock-Chye
Barton, Anne
Worthington, Jane
Emery, Paul
author_sort Morgan, Ann W
collection PubMed
description INTRODUCTION: This study investigated five confirmed rheumatoid arthritis (RA) susceptibility genes/loci (HLA-DRB1, PTPN22, STAT4, OLIG3/TNFAIP3 and TRAF1/C5) for association with susceptibility and severity in an inception cohort. METHODS: The magnitude of association for each genotype was assessed in 1,046 RA subjects from the Yorkshire Early RA cohort and in 5,968 healthy UK controls. Additional exploratory subanalyses were undertaken in subgroups defined by autoantibody status (rheumatoid factor and anti-cyclic citrullinated peptide) or disease severity (baseline articular erosions, Health Assessment Questionnaire (HAQ) score and swollen joint count (SJC)). RESULTS: In the total RA inception cohort, the HLA-DRB1 shared epitope (per-allele odds ratio (OR) = 2.1, trend P < 0.0001), PTPN22 (per-allele OR = 1.5, trend P < 0.0001), OLIG3/TNFAIP3 locus (per-allele OR = 1.2, trend P = 0.009) and TRAF1/C5 locus (per-allele OR = 1.1, trend P = 0.04) were associated with RA. The magnitude of association for these loci was increased in those patients who were autoantibody-positive. PTPN22 was associated with autoantibody-negative RA (per-allele OR = 1.3, trend P = 0.04). There was no evidence of association between these five genetic loci and baseline erosions or SJC in the total RA cohort, after adjustment for symptom duration. TRAF1/C5 was significantly associated with baseline HAQ, however, following adjustment for symptom duration (P trend = 0.03). CONCLUSIONS: These findings support the mounting evidence that different genetic loci are associated with autoantibody-positive and autoantibody-negative RA, possibly suggesting that many of the genes identified to date are associated with autoantibody production. Additional studies with a specific focus on autoantibody-negative RA will be needed to identify the genes predisposing to this RA subgroup. The TRAF1/C5 locus in particular warrants further investigation in RA as a potential disease severity locus.
format Text
id pubmed-2888207
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28882072010-06-21 Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception cohort Morgan, Ann W Robinson, James I Conaghan, Philip G Martin, Stephen G Hensor, Elizabeth MA Morgan, Michael D Steiner, Lori Erlich, Henry A Gooi, Hock-Chye Barton, Anne Worthington, Jane Emery, Paul Arthritis Res Ther Research article INTRODUCTION: This study investigated five confirmed rheumatoid arthritis (RA) susceptibility genes/loci (HLA-DRB1, PTPN22, STAT4, OLIG3/TNFAIP3 and TRAF1/C5) for association with susceptibility and severity in an inception cohort. METHODS: The magnitude of association for each genotype was assessed in 1,046 RA subjects from the Yorkshire Early RA cohort and in 5,968 healthy UK controls. Additional exploratory subanalyses were undertaken in subgroups defined by autoantibody status (rheumatoid factor and anti-cyclic citrullinated peptide) or disease severity (baseline articular erosions, Health Assessment Questionnaire (HAQ) score and swollen joint count (SJC)). RESULTS: In the total RA inception cohort, the HLA-DRB1 shared epitope (per-allele odds ratio (OR) = 2.1, trend P < 0.0001), PTPN22 (per-allele OR = 1.5, trend P < 0.0001), OLIG3/TNFAIP3 locus (per-allele OR = 1.2, trend P = 0.009) and TRAF1/C5 locus (per-allele OR = 1.1, trend P = 0.04) were associated with RA. The magnitude of association for these loci was increased in those patients who were autoantibody-positive. PTPN22 was associated with autoantibody-negative RA (per-allele OR = 1.3, trend P = 0.04). There was no evidence of association between these five genetic loci and baseline erosions or SJC in the total RA cohort, after adjustment for symptom duration. TRAF1/C5 was significantly associated with baseline HAQ, however, following adjustment for symptom duration (P trend = 0.03). CONCLUSIONS: These findings support the mounting evidence that different genetic loci are associated with autoantibody-positive and autoantibody-negative RA, possibly suggesting that many of the genes identified to date are associated with autoantibody production. Additional studies with a specific focus on autoantibody-negative RA will be needed to identify the genes predisposing to this RA subgroup. The TRAF1/C5 locus in particular warrants further investigation in RA as a potential disease severity locus. BioMed Central 2010 2010-03-30 /pmc/articles/PMC2888207/ /pubmed/20353580 http://dx.doi.org/10.1186/ar2969 Text en Copyright ©2010 Morgan et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research article
Morgan, Ann W
Robinson, James I
Conaghan, Philip G
Martin, Stephen G
Hensor, Elizabeth MA
Morgan, Michael D
Steiner, Lori
Erlich, Henry A
Gooi, Hock-Chye
Barton, Anne
Worthington, Jane
Emery, Paul
Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception cohort
title Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception cohort
title_full Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception cohort
title_fullStr Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception cohort
title_full_unstemmed Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception cohort
title_short Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception cohort
title_sort evaluation of the rheumatoid arthritis susceptibility loci hla-drb1, ptpn22, olig3/tnfaip3, stat4 and traf1/c5 in an inception cohort
topic Research article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2888207/
https://www.ncbi.nlm.nih.gov/pubmed/20353580
http://dx.doi.org/10.1186/ar2969
work_keys_str_mv AT morganannw evaluationoftherheumatoidarthritissusceptibilitylocihladrb1ptpn22olig3tnfaip3stat4andtraf1c5inaninceptioncohort
AT robinsonjamesi evaluationoftherheumatoidarthritissusceptibilitylocihladrb1ptpn22olig3tnfaip3stat4andtraf1c5inaninceptioncohort
AT conaghanphilipg evaluationoftherheumatoidarthritissusceptibilitylocihladrb1ptpn22olig3tnfaip3stat4andtraf1c5inaninceptioncohort
AT martinstepheng evaluationoftherheumatoidarthritissusceptibilitylocihladrb1ptpn22olig3tnfaip3stat4andtraf1c5inaninceptioncohort
AT hensorelizabethma evaluationoftherheumatoidarthritissusceptibilitylocihladrb1ptpn22olig3tnfaip3stat4andtraf1c5inaninceptioncohort
AT morganmichaeld evaluationoftherheumatoidarthritissusceptibilitylocihladrb1ptpn22olig3tnfaip3stat4andtraf1c5inaninceptioncohort
AT steinerlori evaluationoftherheumatoidarthritissusceptibilitylocihladrb1ptpn22olig3tnfaip3stat4andtraf1c5inaninceptioncohort
AT erlichhenrya evaluationoftherheumatoidarthritissusceptibilitylocihladrb1ptpn22olig3tnfaip3stat4andtraf1c5inaninceptioncohort
AT gooihockchye evaluationoftherheumatoidarthritissusceptibilitylocihladrb1ptpn22olig3tnfaip3stat4andtraf1c5inaninceptioncohort
AT bartonanne evaluationoftherheumatoidarthritissusceptibilitylocihladrb1ptpn22olig3tnfaip3stat4andtraf1c5inaninceptioncohort
AT worthingtonjane evaluationoftherheumatoidarthritissusceptibilitylocihladrb1ptpn22olig3tnfaip3stat4andtraf1c5inaninceptioncohort
AT emerypaul evaluationoftherheumatoidarthritissusceptibilitylocihladrb1ptpn22olig3tnfaip3stat4andtraf1c5inaninceptioncohort